Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients.
Balinas, Cassandra, Cabanas, Helene, Staines, Donald et al. · Journal of translational medicine · 2019 · DOI
Quick Summary
This study looked at immune cells called NK cells in people with ME/CFS, focusing on special channels on their surface called TRPM2 that control calcium flow. Researchers found that ME/CFS patients had higher levels of these TRPM2 channels compared to healthy people, and their NK cells were less effective at fighting infections. When researchers tried two different drugs to modify these channels, the drugs reduced TRPM2 levels but did not improve the cells' ability to fight infections.
Why It Matters
NK cell dysfunction is a hallmark of ME/CFS, and understanding the specific cellular mechanisms—like calcium regulation through TRPM2 channels—may reveal why immune responses are impaired. This research provides potential targets for future therapies aimed at restoring NK cell function and could eventually lead to treatments that improve immune competence in ME/CFS patients.
Observed Findings
TRPM2 and CD38 surface expression was significantly higher on baseline NK cells in ME/CFS patients compared to healthy controls
NK cell cytotoxicity was significantly reduced at baseline in ME/CFS patients
8-Br-ADPR treatment reduced TRPM2 surface expression on CD56BrightCD16Dim/- NK cell subset in ME/CFS group
IL-2 stimulation caused expression changes only in the CD56DimCD16+ NK cell subset
Drug treatments did not restore NK cell cytotoxicity in ME/CFS patients despite modifying TRPM2 expression
Inferred Conclusions
TRPM2 overexpression may represent a compensatory response to underlying calcium homeostasis dysregulation in ME/CFS
An intrinsic impairment in TRPM2 ion channel function may be present in ME/CFS, limiting calcium mobilization critical for NK cytotoxicity
Differential TRPM2 expression patterns across NK cell subtypes suggest their roles may vary in ME/CFS pathomechanism
Remaining Questions
Why does TRPM2 overexpression fail to restore NK cell cytotoxicity despite its role in calcium signaling?
Is the TRPM2 overexpression a primary defect or secondary compensation for another calcium regulation problem?
What This Study Does Not Prove
This study does not prove that TRPM2 overexpression causes ME/CFS or that correcting TRPM2 levels will cure the disease. It does not establish whether the TRPM2 changes are a cause or consequence of immune dysfunction, and the lack of cytotoxicity improvement with drug treatment suggests TRPM2 targeting alone may be insufficient. The small sample size and in vitro design limit generalizability to real-world disease mechanisms.